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Serotypes of group B streptococcus (GBS) that cause urinary tract infection (UTI) are poorly characterized.
We conducted a prospective study of GBS UTI in adults to define the clinical and microbiological character-
istics of these infections, including which serotypes cause disease. Patients who had GBS cultured from urine
over a 1-year period were grouped according to symptoms, bacteriuria, and urinalysis. Demographic data were
obtained by reviewing medical records. Isolates were serotyped by latex agglutination and multiplex PCR-
reverse line blotting (mPCR/RLB). Antibiotic susceptibilities were determined by disc diffusion. GBS was
cultured from 387/34,367 consecutive urine samples (1.1%): 62 patients had bacteriuria of >107 CFU/liter and
at least one UTI symptom; of these patients, 31 had urinary leukocyte esterase and pyuria (others not tested),
50 (81%) had symptoms consistent with cystitis, and 12 (19%) had symptoms of pyelonephritis. Compared with
controls (who had GBS isolated without symptoms), a prior history of UTI was an independent risk factor for
disease. Increased age was also significantly associated with acute infection. Serotyping results were consistent
between latex agglutination and mPCR/RLB for 331/387 (85.5%) isolates; 22 (5.7%) and 7 (1.8%) isolates were
nontypeable with antisera and by mPCR/RLB, respectively; and 45/56 (80.4%) isolates with discrepant results
were typed by mPCR/RLB as belonging to serotype V. Serotypes V, Ia, and III caused the most UTIs; serotypes
II, Ib, and IV were less common. Nontypeable GBS was not associated with UTI. Erythromycin (39.5%) and
clindamycin (26.4%) resistance was common. We conclude that a more diverse spectrum of GBS serotypes
causes UTI than previously recognized, with the exception of nontypeable GBS.
Group B streptococcus (GBS) is a leading cause of infection
in newborns, pregnant women, and older persons with chronic
medical illness (3, 8). In addition to maternal cervicovaginal
colonization and neonatal infection that results from the ver-
tical transmission of bacteria from mothers to their infants,
GBS can also cause urinary tract infection (UTI). The spec-
trum of GBS UTI includes asymptomatic bacteriuria (ABU),
cystitis, pyelonephritis, urethritis, and urosepsis (6, 8, 10, 20,
23, 26). GBS ABU is particularly common among pregnant
women, although those most at risk for cystitis due to GBS
appear to be the elderly and immunocompromised individuals
(8, 9, 25). Despite the uropathogenic nature of GBS, the clin-
ical and microbiological features of GBS UTI, including risk
factors for disease and whether there is a tendency for partic-
ular GBS serotypes to cause UTI, are poorly understood.
Clinically, UTI due to GBS may be indistinguishable from
UTI caused by other uropathogens (25). However, a recent
study of multiple uropathogens and host characteristics high-
lighted unique frequencies of host characteristics in UTI
groups defined by the causal organism (37). This suggests that
the clinical and microbiological features of UTI may differ
depending on the infecting uropathogen. GBS colonization of
the urinary tract in women most likely occurs by an ascending
route from the vagina, where GBS can persist asymptomati-
cally. While the overall prevalence of GBS UTI in the adult
population remains unclear, GBS bacteriuria during pregnancy
occurs at rates of between 1 and 3.5% (4, 23, 41). Many of
these episodes represent ABU (2, 18); however, GBS ABU is
considered to be a surrogate for heavy maternal colonization
(29, 42) and is currently recommended for intrapartum antibi-
otic chemoprophylaxis (23, 34). In addition, up to 7% of preg-
nancies may be complicated by GBS UTI, and GBS reportedly
accounts for approximately 10% of all cases of pyelonephritis
during pregnancy (25, 28). GBS UTI may also contribute to
chorioamnionitis (1), premature onset of labor (24), and an
increased risk of vertical transmission of GBS (29, 42).
Several studies have also reported high rates of GBS UTI in
nonpregnant adults (8, 9, 25, 39). In one study, GBS was
cultured from 39% of all cases of symptomatic UTI among
nursing home residents 70 years of age (40). Other studies
reported that GBS UTI may account for up to one-third of all
invasive infections due to GBS in adults (9, 12, 19, 26). Several
independent surveys have reported the recovery of GBS from
between 1 and 2% of all UTI cases (7, 26, 30). GBS UTI may
also account for up to 7% of late-onset disease in neonates
(43). Thus, while there is an increasing amount of data regard-
ing the prevalence of GBS UTI in adults, little is known re-
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garding the clinical and microbiological features associated
with these infections or the GBS serotypes that cause UTI. In
this study, we carried out a single-center analysis of adult
patients at the University of Alabama at Birmingham Hospital
between August 2007 and August 2008 who had GBS cultured
from urine during routine assessments for UTI to define the
clinical and microbiological characteristics of GBS UTI includ-
ing which serotypes cause disease.
MATERIALS AND METHODS
Patients. The study subjects were adult patients (18 years of age) encoun-
tered at the University of Alabama at Birmingham Hospital between August
2007 and August 2008 who underwent clinical and microbiological assessments
for UTI because of symptoms indicating infection or as part of routine patient
screening. Urine samples were obtained as clean-catch voided or catheterized
samples from all adult patients who underwent assessment for UTI during the
study period. This included inpatients, patients that were evaluated in the emer-
gency department, and patients from various University Hospital outpatient
clinics. In cases where GBS was cultured from urine (any count), the medical
records for each patient were reviewed for presenting symptoms at the time of
sample collection, and demographic data including possible risk factors were
recorded. A provisional UTI diagnosis was defined by the presence of single-
organism GBS bacteriuria (107 CFU/liter) with at least one symptom that
included dysuria, increased urinary frequency and/or urgency, fever of 38°C,
flank pain, and/or lumbar tenderness. In cases where urinalysis (UA) was per-
formed, UTI was confirmed on the basis of positive urinary leukocyte esterase
and pyuria (107 white blood cells/high-power field; nonspun). These are the
generally accepted criteria for the diagnosis of UTI (11, 14, 21). Patients were
grouped into probable GBS UTI where UA was not performed and confirmed
cases where (positive) UA data were available. This study was performed in
accordance with the ethical standards of the University of Alabama Birmingham
committee on human experimentation and the Helsinki Declaration. The need
for specific informed consent was waived by the institutional review board of the
University of Alabama at Birmingham.
Controls. To conduct an analysis of risk factors for GBS UTI, we identified a
group of control subjects who were defined as having GBS isolated from urine
incidentally. These individuals were selected on the basis of low-grade GBS
bacteriuria (107 CFU/liter) in the absence of symptoms. This allowed an as-
sessment of the factors associated with acute GBS UTI versus asymptomatic
genitourinary colonization, which is prevalent among healthy adult women.
Among the total patient cohort who had GBS isolated from urine, there were 51
individuals who satisfied these criteria, and all were included as controls. We also
performed alternative comparisons using a control group of all 325 individuals
who did not satisfy the criteria defined for GBS UTI (“all others,” subjects who
were GBS culture positive but did not have acute symptomatic UTI as defined by
the exclusion criteria).
Bacterial isolates. All isolates were cultured from clean-catch voided urine or
a catheterized urine sample. Isolates were identified by typical colony morphol-
ogy on tryptic soy agar–5% sheep blood agar plates (BD), tested for catalase, and
grouped using the Remel PathoDx latex agglutination kit. Capsular serotyping of
each GBS isolate was performed by latex agglutination using commercial anti-
sera from SSI (Denmark) as described elsewhere previously (36). Antimicrobial
susceptibility testing was performed by disc diffusion according to methods of the
Clinical and Laboratory Standards Institute (41a). One isolate per patient was
analyzed and stored at 80°C in 15% glycerol in Todd-Hewitt broth. Strains
were grown at 37°C on Todd-Hewitt agar or in Todd-Hewitt broth.
Molecular serotyping. Molecular serotypes (MSs) were determined at the
Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology
and Medical Research, Sydney, NSW, Australia, for each GBS isolate (17). The
MS identification of 10 serotypes (MS Ia, Ib, and II to IX) was determined by
using a multiplex PCR and reverse line blot (mPCR/RLB) hybridization assay
targeting a GBS species-specific gene (cfb) and serotype-specific sequences in
various genes: cpsH for MSs Ia, Ib, III, IV, V, VI, and IX; cpsK for MS II; cpsM
for MS VII; and cpsJ for MS VIII. Methods for the extraction of GBS genomic
DNA were described elsewhere previously (15), along with sequences of oligo-
nucleotides, primers, probes, and optimal PCR and hybridization conditions
(17).
Discrepancies between latex agglutination and mPCR/RLB. Isolates were
tested independently by the two methods without knowledge of the results of the
other method. When discrepancies were identified, both were repeated, and if
discrepancies persisted, a portion of the cpsE-cpsF-cpsG gene cluster was se-
quenced (800 bp) to confirm the result (44). The mPCR/RLB result was
accepted as the definitive result.
Statistical analysis. We used SPSS v9.0 for statistical analyses. Differences in
categorical variables (i.e., risk factors) between case patients and control subjects
were examined by Pearson chi-squared (2) analysis or Fisher’s exact test where
the expected value of any cell was below 5. For continuous variables without
normal distribution (i.e., age), a Mann-Whitney U test was used. Gender com-
parisons were performed using population data (equal group sizes assumed)
from the U.S. Census Bureau for Birmingham, AL (male-to-female ratio, 0.857).
The quantitative effects of covariates on variables identified as being significant
by univariate analysis were evaluated by logistic regression to identify indepen-
dent risk factors for GBS UTI. Results are given as adjusted odds ratios (ORs).
P values of 0.05 were regarded as being significant.
RESULTS
Study population. A total of 34,367 urine samples were
collected from patients who underwent assessment for UTI
during the study period. These samples represented a total
patient cohort of inpatients (39%), outpatients (19.6%),
women in obstetrics care (27.4%), and patients who presented
to emergency rooms (14%). GBS was cultured from 387 pa-
tients (1.1%), representing both clean-catch voided (346/387
[89.4%]) and catheterized (41/387 [10.6%]) samples. The de-
mographic data for the cohort of 387 GBS-positive patients are
summarized in Table 1. The mean age for the 387 patients was
46 years (range, 18 to 95 years), and 322/387 patients (83.2%)
were female. The most common comorbid conditions were
urological (21.4%), cardiac (17.6%), neurological (15.5%), en-
docrine (8.5%), and pulmonary (7.8%). The cohort of 387
patients with urine cultures that were positive for GBS in-
cluded inpatients (18.8%), outpatients (52.4%), women in ob-
stetrics care (21%), and patients who presented to emergency
rooms (7.8%). Among the 387 patients with urine cultures that
were positive for GBS, 207 (53.5%) had single-organism GBS
cultured, and 210 (54.3%) underwent UA. The most com-
monly found cocultured organisms were Escherichia coli
(6.7%), coagulase-negative staphylococci (5.7%), diptheroids
(4.4%), Lactobacillus spp. (3.4%), Klebsiella pneumoniae
(2.8%), Staphylococcus aureus (2.6%), and viridans group
streptococci (2.6%).
Cases of GBS UTI. Among 387 patients with urine cultures
that were positive for GBS, 62 patients had single-organism
GBS bacteriuria with 107 CFU/liter concurrent with at least
one UTI symptom and were defined as having probable GBS
UTI. Among these, 50/62 patients (81%) had clinical and mi-
crobiological features consistent with cystitis, versus 12/62
(19%) for pyelonephritis (Table 1). All 31 of the 62 patients
who had UA performed had positive results based on positive
urinary leukocyte esterase and pyuria (Table 1). None of the 62
cases were associated with an indwelling urinary catheter, and
only one patient had GBS concurrently isolated from blood,
representing probable urosepsis.
Risk factor analysis. When 62 case patients were compared
with 51 controls (Table 1), the mean age of case patients was
significantly greater (53  19 years versus 30  12 years; P 
0.001). However, there were no significant differences in the
prevalence rates of previously identified (and several other
potential) risk factors including limited mobility, diabetes mel-
litus, chronic kidney disease, and the presence of an indwelling
urinary catheter between case patients and control subjects
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(Table 1). GBS UTI case patients were significantly more likely
to have had a prior history of UTI than controls (OR, 3.1; 95%
confidence interval [CI], 1.1 to 8.7) and to be female (OR, 3.8;
95% CI, 1.6 to 8.7). A prior history of UTI was highly signif-
icant among pyelonephritis case patients (50.0% [6/12] versus
11.8% [6/51]; P  0.007) compared to controls and was an
independent risk factor for GBS pyelonephritis (OR, 10.1;
95% CI, 1.9 to 54.4). Significantly fewer women of child-bear-
ing age (defined as40 yrs) with GBS UTI were pregnant than
women of child-bearing age who were controls (37.5% [6/16]
versus 81.4% [35/43]; P  0.003). No significant effects of race
were observed (data not shown). Overall, these results were
consistent with an alternative analysis where we compared 62
GBS UTI case patients to “all other patients” who were GBS
culture positive but did not have acute symptomatic GBS UTI
as defined by the exclusion criteria (n 325) (data not shown).
GBS serotypes and capsular sequence types. Twenty-two of
387 (5.7%) isolates were nontypeable (NT) by latex agglutina-
tion, and 7 (1.8%) were NT by mPCR/RLB. Results were
consistent between the two methods for 331/387 (85.5%) iso-
lates. After retesting by both methods, 45/56 (80.4%) isolates
for which results were discrepant were serotyped by mPCR/
RLB as being serotype V after being NT (16) or identified as
other serotypes (serotype VIII, 15 isolates; serotype II, 6 iso-
lates; and serotypes Ia, Ib, IV, and III, 2 isolates each) by latex
agglutination. Four isolates that were NT by mPCR/RLB were
TABLE 1. Adult patients who had GBS isolated from urine during routine assessment for UTI at the University of Alabama Hospital
between August 2007 and August 2008
Parameter
Value for groupc
P value (all cases
vs controls)Total specimens
(n  387)a
GBS UTI casesb
Controlsd (n  51)
UA vec (n  31) UA NDk (n  31) All (n  62)
Age (yr) (mean; range) 46; 18–95 54; 19–82 52; 19–93 53; 19–93 30; 18–64 0.001g
No. (%) of females 322 (83) 25 (81) 27 (87) 52 (84) 46 (90) 0.002h
No. (%) of patients with symptom:
Dysuria 68 (17.6) 18 (58.1) 17 (54.8) 35 (56.5) 0 (0) ND
Frequency 57 (14.7) 11 (35.5) 12 (38.7) 23 (37.1) 0 (0) ND
Flank pain 35 (9.0) 7 (22.6) 7 (22.6) 14 (22.6) 0 (0) ND
Fever 15 (4.0) 4 (13.0) 2 (6.0) 6 (10.0) 0 (0) ND
C/W cystitise 130 (33.6) 25 (80.6) 24 (77.4) 50 (81.0) 0 (0) ND
C/W pyleonphritisf 65 (16.8) 6 (19.4) 7 (22.6) 12 (19.0) 0 (0) ND
No. (%) of pregnant patients 99 (30.1) 1 (4) 5 (18.5) 6 (11.5) 35 (76)
No. (%) of patients with possible risk
factor of:
Limited mobility 13 (3.4) 1 (3.2) 0 (0) 1 (1.6) 0 (0) 1.000
Diabetes mellitus 91 (23.5) 5 (16.1) 4 (12.9) 9 (14.5) 9 (17.6) 0.651
Chronic kidney disease 72 (18.6) 4 (12.9) 0 (0) 4 (6.5) 7 (13.7) 0.219
Indwelling urinary catheter 4 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) ND
Altered mental status 14 (3.6) 3 (9.7) 2 (6.5) 5 (8.1) 0 (0) 0.063i
Prior history of UTI 76 (19.6) 9 (29.0) 9 (29.0) 18 (29.0) 6 (11.8) 0.032j
Pure GBS isolated 207 (53.5) 31 (100) 31 (100) 62 (100) 15 (29.4) ND
No. (%) of patients with GBS counts of
107 CFU/liter
319 (82.4) 31 (100) 31 (100) 62 (100) 0 (0) ND
Mean GBS count (	 107 CFU/liter)  SD 4.7  3.6 7.4 3.5 6.1 3.1 6.7  3.4 0.5  0.3 ND
No. (%) of patients with UA done 210 (54.3) 31 (100) 0 (0) 31 (50) 9 (17.3) ND
No. (%) of patients with finding:
Pyuria 114 (54.3) 31 (100) ND 31 (100) 0 (0) ND
Leukocyte esterase 122 (58.1) 31 (100) ND 31 (100) 0 (0) ND
Hematuria 74 (35.2) 21 (67.7) ND 21 (67.7) 2 (22) ND
ve and C/W UTIe, f 91 (43.3) 31 (100) ND 31 (100) 0 (0) ND
a Consecutive urine specimens sent for culture from which GBS was isolated.
b Patients with at least one symptom of UTI and pure growth of GBS of 107 CFU/liter.
c ve (consistent with UTI), positive for leukocyte esterase and pyuria.
d Subjects without symptoms from whose urine GBS was isolated in counts of 107 CFU/liter.
e Symptoms consistent with (C/W) cystitis are dysuria and/or frequency.
f Symptoms consistent with pyelonephritis are dysuria and/or frequency plus flank pain and/or fever of 38°C.
g Determined by Mann-Whitney U test.
h Determined by Pearson 2 analysis. Gender comparisons were performed using population data (equal group sizes) from the U.S. Census Bureau for Birmingham
(male-to-female ratio, 0.857).
i Determined by Fisher’s exact test.
j Determined by forward stepwise logistic regression subsequent to Pearson 2 analysis.
k ND, not done.
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identified, using antisera, as being serotypes II (two isolates),
IV (one isolate), and V (one isolate). Mismatches for other
isolates were as follows (latex agglutination-mPCR/RLB
shown): serotype II-serotype Ia (two isolates), serotype II-
serotype III (one isolate), serotype IV-serotype II (one iso-
late), NT-serotype Ia (two isolates), and NT-serotype Ib (one
isolate). A total of three isolates were identified as being NT by
both methods. Discrepant results for the most common mis-
match (serotype VIII-serotype V) were confirmed by sequenc-
ing of the mPCR amplicon. The mPCR/RLB serotyping results
were accepted as definitive and are shown in Table 2.
The most prevalent serotypes among the 62 cases of GBS
UTI were serotypes V, Ia, and III (Table 2), which together
account for 76% of cases. Serotypes II, Ib, and IV accounted
for the remaining 24% of cases. Serotype III and V GBS were
the only serotypes that were more frequently isolated from
UTI case patients than from controls (21% versus 10% and
32% versus 20%, respectively) (Table 2), but the differences
were not significant. The trend of an increased prevalence of
serotype III GBS was statistically significant when we com-
pared 62 GBS UTI case patients with “all other patients” who
were GBS culture positive but did not have acute symptomatic
GBS UTI as defined by the exclusion criteria (21% [13/62]
versus 10.8% [35/325]; P  0.026), but there was no difference
in the prevalence of serotype V GBS between case patients and
“all other patients” (32% [20/62] versus 32.3% [105/325]; P 
0.994).
Antibiotic susceptibilities. Disc diffusion analysis of all 387
GBS isolates demonstrated that they were uniformly suscepti-
ble to amoxicillin (amoxicilline) with clavulanic acid, penicillin,
linezolid, and chloramphenicol. A considerable proportion of
isolates was resistant to clindamycin (102/387 [26.4%]) and
erythromycin (153/387 [39.5%]), and the majority was resistant
to tetracycline (311/387 [80.4%]), cefoxitin (343/387 [88.7%]),
and trimethoprim with sulfamethoxazole (380/387 [98.3%]).
DISCUSSION
The uropathogenic potential of GBS prompted the current
study to better define the clinical and microbiological features
of GBS UTI and the serotypes that are predominately associ-
ated with disease. Among 387 patients who had GBS cultured
from urine, we identified 62 UTI cases on the basis of single-
organism bacteriuria and symptoms; diagnosis was confirmed
in half of these cases where UA was performed. Diagnostic
strategies for UTI vary substantially between clinicians (11, 14,
21); however, patients with a combination of symptoms have a
high probability of UTI (5, 27). Pyuria concurrently with bac-
teriuria may constitute diagnostic criteria (35), as does 106
CFU/liter of a uropathogen for cystitis (27, 33). We regarded
single-organism GBS bacteriuria of 107 CFU/liter and at
least one UTI symptom as being a probable case of UTI and
used urinary leukocyte esterase with significant pyuria as being
confirmatory for diagnosis. Our criteria excluded contami-
nated samples and low-grade ABU, which are especially com-
mon among urine cultures that are positive for GBS (2, 28, 29)
and elderly individuals (13). The majority of 62 GBS UTI cases
in this study were uncomplicated cystitis, although diagnostic
features for pyelonephritis (27) identified this in almost 20% of
cases overall. It is noteworthy that our exclusion criteria lim-
ited the GBS UTI case definition to only those patients with
single-organism GBS bacteriuria. Based on the prevalence of
single-organism cultures and the ratio of GBS UTI to ABU
(1:2), it is likely that up to one-third and one-quarter of the 387
urine cultures that were positive for GBS in this study repre-
sent GBS UTI and ABU, respectively. The total isolation rate
of GBS from 34,367 urine cultures of 1.1% in this study is
consistent with data from previous reports on the prevalence of
GBS UTI among adults (7, 26, 30).
Several patients in this study with multiple symptoms of UTI
and positive UA findings had GBS bacteriuria of between 107
and 108 CFU/liter, which is consistent with reports that up to
30% of women with cystitis present with bacteriuria of 108
CFU/liter. In addition, there were several symptomatic pa-
tients who presented with clinical features consistent with
acute cystitis including positive UA findings but who were
excluded from our case definition of GBS UTI because of
single-organism bacteriuria of only between 106 and 107 CFU/
liter at the time of analysis. For one such patient, GBS bacte-
riuria increased fourfold over a 6-h period, highlighting the
dynamic nature of bacteriuria as an indicator of GBS UTI.
These findings support the notion that low-grade bacteriuria
(106 CFU/liter) of a uropathogen including GBS may be
indicative of cystitis in symptomatic individuals (5, 27, 33).
Urinary tract abnormalities, chronic renal failure (26), dia-
betes mellitus (32), and corticosteroid use (9) are among risk
factors previously associated with GBS UTI. In this study, the
rate of diabetes and chronic kidney disease among GBS UTI
case patients did not differ significantly from the rate among
control subjects who had GBS isolated from urine in the ab-
sence of symptoms. Multivariate analysis, however, revealed
significant effects of a prior history of UTI, which is compara-
TABLE 2. Molecular serotyping data for GBS UTI isolates
in this study
GBS
serotype
No. (%) of GBS isolatesc
All
specimens
(n  387)a
GBS UTI casesb
Controlsd
(n  51)UA vec
(n 31)
UA NDg
(n  31)
All
(n  62)
Ia 81 (21) 6 (19) 8 (26) 14 (23) 8 (16)
Ib 31 (8) 2 (7) 3 (10) 5 (8) 5 (10)
II 69 (18) 5 (16) 3 (10) 7 (11) 12 (24)
III 48 (12)e 8 (26) 5 (16) 13 (21)e 5 (10)
IV 24 (6) 2 (7) 1 (3) 3 (5) 5 (10)
V 125 (32) 8 (26) 12 (37) 20 (32) 10 (20)
VI 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VII 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VIII 2 (1) 0 (0) 0 (0) 0 (0) 1 (2)
NTf 7 (2) 0 (0) 0 (0) 0 (0) 5 (10)
IX 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
a Consecutive urine specimens sent for culture from which GBS was isolated.
b Patients with at least one symptom of UTI and pure growth of GBS of 107
CFU/liter.
c ve (consistent with UTI), positive for leukocyte esterase and pyuria.
d Subjects without symptoms from whose urine GBS was isolated in counts of
107 CFU/liter.
e Difference between the prevalence of serotype III among all GBS UTI case
patients and all other non-GBS UTI cases (n 325), determined to be significant
by Pearson 2 analysis (P  0.026).
f These isolates were identified using antisera as being NT (three isolates) or
belonging to serotypes II (two isolates), IV (one isolate), and V (one isolate).
g ND, not done.
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ble to data from studies that have identified a history of UTI as
being a risk factor for disease caused by other uropathogens
including Enterobacter cloacae (37). Increased age was also
significantly associated with GBS UTI.
Nontypeable and serotype III GBS have been identified as
being causes of UTI (23, 29). In this study, serotype III was the
only type that was more frequently associated with acute dis-
ease than other serotypes. Future molecular studies will be
important to determine the clonal types of serotype III uro-
pathogenic GBS since only a few clones cause early- and late-
onset neonatal disease (38). Recovery of multiple additional
serotypes from case patients, particularly of serotypes II, V,
and Ia, shows for the first time that a broader spectrum of GBS
serotypes causes UTI than previously recognized. Notably, NT
GBS accounted for no cases of GBS UTI in this study, in
contrast to data from previous reports (23, 29). Molecular
serotyping is more specific than antiserum-based assays (17),
which are confounded by variable expression and partial shar-
ing of GBS capsular antigens. It is possible that high preva-
lence rates of NT GBS among patients with UTI in previous
studies may represent novel MSs that could not be classified by
agglutination approaches. Very few GBS isolates are NT by
mPCR/RLB; those that are can usually be shown to have
mutations in the serotype-specific target region. The high pro-
portion of MS V isolates that were NT or gave conflicting
results with latex agglutination is consistent with results of a
recent study (16). In a large collection of NT GBS isolates, we
showed that serotype V was the most common MS identified.
Reactions of these isolates with discordant antisera (especially
serotype VIII) may reflect low titers of antisera and/or cross-
reactivity. These findings underscore the limitations of agglu-
tination serotyping approaches for some GBS in epidemiolog-
ical surveys (15).
A high rate of resistance to macrolides was observed among
GBS isolates in this study. These findings are consistent with a
recent survey of GBS in the United States, where Manning et
al. demonstrated higher-than-expected frequencies of macro-
lide resistance among GBS in nonpregnant women (22).
Trends of increasing antibiotic resistance may reflect clonal
dissemination and horizontal transfer of resistance genes
among GBS, which occurs among certain GBS serotypes (31).
In summary, GBS UTI in this study occurred mostly as
uncomplicated cystitis in women over the age of 50 years in the
absence of chronic underlying disease but was associated with
a prior history of UTI. GBS UTI was caused by a more diverse
spectrum of serotypes than previously recognized, with the
exception of NT GBS. Relatively high rates of treatment fail-
ure and poor clinical outcomes have been associated with GBS
UTI (26). Further longer-term surveillance studies will help to
better define the clinical features and serotypes associated with
these important infections.
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